RAPP
Rapport Therapeutics, Inc.Company Information
- Company Name
- Rapport Therapeutics, Inc.
- CIK
- CIK0002012593
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- RAPP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RAPP
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-09-12
- Last sale
- 2026-09-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 846,542
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 50,307,913
- Shares outstanding
- 47,473,174
- Ownership
- 105.97%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 14.92%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 64 | 78 | 53 | 251 | 55 | 58 | 57 | 39 | 110 | ||||||
| Accounts Receivable Net Current | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Short Term Investments | 372 | 399 | 438 | 262 | 205 | 228 | 248 | 281 | 226 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 10 | 8 | 8 | 8 | 10 | 5 | 4 | 5 | 4 | ||||||
| Assets Current | 447 | 485 | 499 | 521 | 270 | 291 | 310 | 326 | 341 | ||||||
| Property Plant And Equipment Net | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | ||||||
| Operating Lease Right Of Use Asset | 9 | 9 | 10 | 10 | 11 | 7 | 1 | 2 | 2 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets | 459 | 498 | 512 | 535 | 285 | 302 | 315 | 331 | 346 | ||||||
Liabilities Current | |||||||||||||||
| Accounts Payable Current | 3 | 7 | 4 | 3 | 3 | 2 | 2 | 1 | 2 | ||||||
| Accrued Liabilities Current | 23 | 9 | 12 | 9 | 7 | 6 | 6 | 5 | 6 | ||||||
| Operating Lease Liability Current | 2 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 28 | 18 | 19 | 14 | 12 | 9 | 9 | 7 | 8 | ||||||
| Operating Lease Liability Noncurrent | 8 | 8 | 9 | 9 | 10 | 7 | 1 | 1 | 1 | ||||||
| Liabilities | 36 | 26 | 28 | 24 | 22 | 16 | 10 | 8 | 9 | ||||||
Stockholders Equity | |||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | - | 0 | - | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 736 | 727 | 719 | 713 | 438 | 434 | 430 | 426 | 423 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | 1 | 0 | -0 | -0 | -1 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -312 | -255 | -235 | -201 | -175 | -148 | -124 | -104 | -86 | ||||||
| Stockholders Equity | 423 | 472 | 485 | 512 | 264 | 286 | 305 | 323 | -337 | ||||||
| Liabilities And Stockholders Equity | 459 | 498 | 512 | 535 | 285 | 302 | 315 | 331 | 346 | ||||||
| Series A Convertible Preferred Stock | - | - | - | - | - | - | 0 | -0 | 0 | ||||||
| Series B Convertible Preferred Stock | - | - | - | - | - | - | 0 | -22 | 22 | ||||||
| Third Rock Ventures L L C | - | - | - | 0 | 0 | - | 0 | 0 | 0 | ||||||
| Maximum | - | - | 0 | - | - | - | 0 | 0 | 0 | ||||||
| Minimum | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | - | 10 | - | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | - | 0 | - | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | - | 0 | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 48 | 48 | 48 | 48 | 36 | 36 | 37 | 37 | 37 | ||||||
| Shares Outstanding | 48 | 48 | 48 | 48 | 36 | 36 | 37 | 37 | 37 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRapport Therapeutics, Inc. (RAPP) — SEC Financial Statements & Analysis
Rapport Therapeutics, Inc. (RAPP) is a pharmaceutical preparations company, incorporated in DE. Rapport Therapeutics, Inc. trades on Nasdaq as: RAPP. Rapport Therapeutics, Inc. (RAPP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Rapport Therapeutics, Inc. carries a market cap of $1.98B, a P/E ratio of -14.42x, a P/B ratio of 4.68x, a P/S ratio of 98.91x, an enterprise value of $1.91B, and an EV/EBITDA multiple of -12.55x. On profitability, it posts an operating margin of -767.58%, a net margin of -685.80%, a Return on Equity (ROE) of -39.96%, a Return on Assets (ROA) of -36.85%, and a Return on Invested Capital (ROIC) of -54.04%. Per share, it reports EPS of $-2.89, diluted EPS of $-2.89, free cash flow per share of $-2.05, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 23.59% year-over-year and EPS growth of -7.73% year-over-year. On the balance sheet, it maintains a current ratio of 15.72x, a quick ratio of 15.36x, working capital of $418.43M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-97.15M (TTM), and net debt of $-63.61M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.98B
- P/E TTM
- -14.42x
- EPS TTM
- $-2.89
- P/B TTM
- 4.68x
- ROE TTM
- -39.96%
- ROA TTM
- -36.85%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-97.15M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Rapport Therapeutics, Inc. in?
Rapport Therapeutics, Inc. (RAPP) operates in the Pharmaceutical Preparations industry.
What exchange does RAPP trade on?
Rapport Therapeutics, Inc. (RAPP) trades on the Nasdaq.
Where is Rapport Therapeutics, Inc. incorporated?
Rapport Therapeutics, Inc. is incorporated in DE.
When was Rapport Therapeutics, Inc. (RAPP)'s most recent SEC filing?
Rapport Therapeutics, Inc. (RAPP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is RAPP's market cap?
Rapport Therapeutics, Inc. (RAPP) has a market capitalization of $1.98B as of 2026-06-30.
What is RAPP's EPS (earnings per share)?
Rapport Therapeutics, Inc. (RAPP)'s trailing twelve month EPS is $-2.89 as of 2026-06-30.
What is RAPP's ROE (return on equity)?
Rapport Therapeutics, Inc. (RAPP)'s trailing twelve month Return on Equity (ROE) is -39.96% as of 2026-06-30.
What is RAPP's ROA (return on assets)?
Rapport Therapeutics, Inc. (RAPP)'s trailing twelve month Return on Assets (ROA) is -36.85% as of 2026-06-30.
What is RAPP's ROIC (return on invested capital)?
Rapport Therapeutics, Inc. (RAPP)'s trailing twelve month Return on Invested Capital (ROIC) is -54.04% as of 2026-06-30.
What is RAPP's EV/EBITDA?
Rapport Therapeutics, Inc. (RAPP)'s trailing twelve month EV/EBITDA is -12.55x as of 2026-06-30.